Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00466791 · ClinicalTrials.gov registry record · Phase 2

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

A Phase 2 study of Attention Deficit Disorder With Hyperactivity, sponsored by Noven Therapeutics.

Completed
Registry status
Phase 2
Development phase
93
Enrollment target
1
Study location

NCT00466791 is a Phase 2 study of Attention Deficit Disorder With Hyperactivity that has completed, run by Noven Therapeutics. The registered enrollment target is 93 participants, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00466791, a Phase 2 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Noven Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
93 participants
Enrollment target
1
Study location

Study Summary

Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD

Interventions

  • DRUG Methylphenidate Transdermal System

Study Locations (1)

California

  • UCI Child Development Center - Irvine

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2004-08
Est. Completion 2005-05
Phase Phase 2

Sponsor

Noven Therapeutics

10 total trials

What the Registry Record Tells You About NCT00466791

The ClinicalTrials.gov registry entry for NCT00466791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower). The listed sponsor is Noven Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate Transdermal System is the first listed.

NCT00466791 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00466791 about?

NCT00466791 is a clinical study titled "Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD". Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD

What is the current status of trial NCT00466791?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2004-08. Estimated completion is 2005-05.

What conditions does trial NCT00466791 study?

This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.

What interventions are being tested in trial NCT00466791?

The interventions under investigation include: Methylphenidate Transdermal System (DRUG).

Who is sponsoring clinical trial NCT00466791?

This trial is sponsored by Noven Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00466791 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Disorder With Hyperactivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.